Abedalrahman Maen Addassi: Edoxaban’s Journey Shows How Targeted Pharmacology and Real-World Data Converge
Abedalrahman Maen Addassi, Pharmacist, shared a post on LinkedIn:
”Innovation in Anticoagulation: Edoxaban by Daiichi Sankyo
In a world where stroke prevention and venous thromboembolism management are critical, Edoxaban (Savaysa) stands out as a once-daily oral anticoagulant that’s reshaping clinical practice.
- FDA Approval Date: January 8, 2015 A B
- Mechanism of Action: Edoxaban is a direct Factor Xa inhibitor, selectively blocking a key step in the coagulation cascade to prevent thrombus formation C.
Indications:
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial parenteral anticoagulation A B
Side Effects:
- Most common: bleeding, including gastrointestinal and intracranial hemorrhage
- Others: anemia, rash, liver enzyme elevation—requiring careful renal function monitoring, especially in patients with CrCL >95 mL/min B
How Does It Compare?
- Warfarin: Edoxaban showed non-inferior efficacy with lower rates of major bleeding in ENGAGE AF-TIMI 48 trial B
- Rivaroxaban and Apixaban: All are Factor Xa inhibitors, but edoxaban offers once-daily dosing and a favorable bleeding profile in select populations
- Dabigatran: A direct thrombin inhibitor—different mechanism, twice-daily dosing, and higher GI bleeding risk
Backed by global trials like ENGAGE AF-TIMI 48 and Hokusai-VTE, edoxaban continues to expand its footprint across more than 40 countries C.
As a recent pharmacy graduate passionate about medical information and therapeutic innovation, I find edoxaban’s journey a powerful example of how targeted pharmacology and real-world data can converge to improve patient outcomes.
Let’s connect if you’re working in anticoagulation, clinical trials, or medical affairs—I’d love to exchange insights!”
Stay updated with Hemostasis Today.
-
Nov 6, 2025, 08:24Jacqui McCallum Reflects on Meeting with The Royal Melbourne Hospital Stroke and Neurology Ward Team
-
Nov 6, 2025, 08:17Maxime Dely: The True Heroes of Blood Donation Are Them!
-
Nov 6, 2025, 07:11Francesco Giurazza on Radial Access for Liver Transarterial Chemoembolization
-
Nov 6, 2025, 07:04Andrea Van Beek: Proud to be a Certified Anticoagulation Care Provider (CACP)!
-
Nov 6, 2025, 06:57Jian-Ke Tie’s Team on Comorbidity of VitK-dependent Clotting Factors Deficiency and Chondrodysplasia Punctata
-
Nov 6, 2025, 04:17Aakanksha A To Present Insights from ASH Education Social Media Initiative at 67th ASH Meeting
-
Nov 6, 2025, 04:03Yaping Zhang on Two-Way GPIb-IX Signaling in Platelet Activation and VWF Binding
-
Nov 6, 2025, 03:38Thierry Burnouf on Platelet-Derived Extracellular Vesicles and Their Role in Neurogenesis
-
Nov 6, 2025, 03:29Shubham Misra to Present 3 Abstracts at International Stroke Conference 2026